Holen Sie sich die Stockscreener-App
40.63
1.26%
-0.54
Exelixis Inc Aktie (EXEL) Neueste Nachrichten
Assessing Exelixis (EXEL) Valuation After Analysts Lift 2026 Earnings Forecasts - simplywall.st
Exelixis (EXEL) Down 2.8% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Here’s What Makes Exelixis (EXEL) a Top Growth Stock - Bitget
Here's Why Exelixis (EXEL) is a Strong Growth Stock - Yahoo Finance
Exelixis at Barclays Healthcare: Strategic Growth and Pipeline Insights By Investing.com - Investing.com Canada
EXEL: Zanzalintinib and CABOMETYX anchor growth in GI/GU oncology, with robust pipeline momentum - TradingView
EXEL: Zanza and new indications drive growth, targeting $2.4B revenue and leadership in key oncology markets - TradingView
First Trust Advisors LP Has $59.35 Million Holdings in Exelixis, Inc. $EXEL - MarketBeat
Barclays PLC Boosts Stock Holdings in Exelixis, Inc. $EXEL - MarketBeat
Exelixis at Leerink Global Healthcare Conference: Strategic Insights in RCC and CRC - Investing.com Canada
Exelixis Q4 2025 slides: Strong earnings growth amid oncology franchise expansion - Investing.com Nigeria
Dimensional Fund Advisors LP Grows Holdings in Exelixis, Inc. $EXEL - MarketBeat
Victory Capital Management Inc. Acquires 187,034 Shares of Exelixis, Inc. $EXEL - MarketBeat
What is Zacks Research's Estimate for Exelixis Q3 Earnings? - MarketBeat
Crossmark Global Holdings Inc. Boosts Stock Position in Exelixis, Inc. $EXEL - MarketBeat
Exelixis, Inc. Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
(EXEL) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Teton Advisors LLC Makes New Investment in Exelixis, Inc. $EXEL - MarketBeat
Exelixis (NASDAQ:EXEL) Cut to Hold at Zacks Research - MarketBeat
Gainers Report: Will Exelixis Inc benefit from rising consumer demandWeekly Trend Summary & Smart Investment Allocation Tips - baoquankhu1.vn
Exelixis, Inc. (NASDAQ:EXEL) Given Average Recommendation of "Hold" by Analysts - MarketBeat
American Century Companies Inc. Raises Position in Exelixis, Inc. $EXEL - MarketBeat
Elo Mutual Pension Insurance Co Buys 30,279 Shares of Exelixis, Inc. $EXEL - MarketBeat
A Look At Exelixis (EXEL) Valuation As Analyst Optimism Builds Around Its Oncology Pipeline - simplywall.st
EXEL: Zanzalintinib advances toward launch as pivotal trials and franchise expansion drive future growth - TradingView
Forecasting The Future: 11 Analyst Projections For Exelixis - Sahm
Is Improving Analyst Sentiment Reframing Exelixis (EXEL) Oncology Pipeline As A Core Valuation Anchor? - simplywall.st
Exelixis (EXEL) EVP Haley granted 40,459 RSUs vesting from 2027 - Stock Titan
Exelixis (NASDAQ: EXEL) CEO granted RSUs, gifts 100K shares - Stock Titan
Exelixis stock falls after rival Merck trial shows better results By Investing.com - Investing.com India
Exelixis stock falls after rival Merck trial shows better results - Investing.com Australia
RBC Capital Lowers Exelixis (EXEL) Price Target to $43 | EXEL St - GuruFocus
Royal Bank Of Canada Issues Pessimistic Forecast for Exelixis (NASDAQ:EXEL) Stock Price - MarketBeat
Why Exelixis (EXEL) Stands Out as a Leading Value Investment for Long-Term Growth - Bitget
Exelixis (NASDAQ:EXEL) Shares Down 9.4% After Analyst Downgrade - MarketBeat
Why Exelixis (EXEL) is a Top Value Stock for the Long-Term - Yahoo Finance
RBC Lowers Price Target on Exelixis to $43 From $46, Keeps Sector Perform Rating - marketscreener.com
Exelixis, Inc. (EXEL) Stock Analysis: Navigating Growth With A 7.05% Potential Upside - DirectorsTalk Interviews
Exelixis (NASDAQ:EXEL) Downgraded by Wall Street Zen to Buy - MarketBeat
Exelixis Aims to Expand Beyond Cabozantinib Franchise - Intellectia AI
Exelixis Aims to Become a Top Oncology Player with Expanding Pipeline - Intellectia AI
3 Reasons Exelixis Stock Could Deliver Market‑Beating Returns Over the Next Decade - Nasdaq
3 Reasons Exelixis Stock Could Deliver Market‑Beating Returns Over the Next Decade - The Motley Fool
Citigroup Inc. Sells 365,552 Shares of Exelixis, Inc. $EXEL - MarketBeat
EXEL PE Ratio & Valuation, Is EXEL Overvalued - Intellectia AI
EXEL Should I Buy - Intellectia AI
Exelixis Director Julie Smith Sells Over 106K Shares - TradingView
Exelixis (NASDAQ:EXEL) EVP Dana Aftab Sells 47,918 Shares - MarketBeat
Exelixis (NASDAQ: EXEL) EVP sells 47,918 shares in open trade - Stock Titan
Exelixis EVP Sells Shares Worth Over $2 Million - TradingView
Intech Investment Management LLC Grows Stake in Exelixis, Inc. $EXEL - MarketBeat
Exelixis Inc (NASDAQ:EXEL) Presents a Compelling Value Investment Case - ChartMill
Is It Too Late To Consider Exelixis (EXEL) After Its Surging Share Price? - Yahoo Finance
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in March 2026 - BioSpace
Exelixis Cancer Pipeline Progress Puts Focus On Valuation And Growth Potential - Yahoo Finance
EXEL (NASDAQ: EXEL) insider Dana T Aftab sells 29,873 shares for $1.32M - Stock Titan
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in March - Business Wire
Oncology Market Set to Nearly Triple: Here Are Five Companies Le - GuruFocus
Oncology Market Set to Nearly Triple: Here Are Five Companies Leading the Charge - PR Newswire
Responsive Playbooks and the EXEL Inflection - Stock Traders Daily
Here's Why Exelixis (EXEL) is a Strong Momentum Stock - Yahoo Finance
Exelixis reports solid earnings – are new highs back on the table? - MSN
Exelixis (NASDAQ:EXEL) EVP Dana Aftab Sells 29,873 Shares - MarketBeat
Exelixis (EXEL) R&D EVP sells 29,873 shares at $44.35 - Stock Titan
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):